Ethics policy
The principles that govern how Reserve Meds decides what to supply, to whom, and under what conditions.
1. Patient-first decision framework
Every case we accept must answer yes to three questions: Is the patient under the care of a licensed treating physician? Is the medicine legally available to that patient via a recognized access pathway in the destination country? Can we source the medicine through a DSCSA-compliant US channel with full unit-level traceability? If any answer is no, we decline.
2. Physician oversight, not direct-to-patient dispensing
Reserve Meds is a named-patient access platform, not a direct-to-consumer pharmacy. We do not fill requests absent a valid prescription from a licensed treating physician, and we do not substitute our clinical judgment for theirs. Patients who approach us without a physician are referred — we do not act as a bypass around standard care.
3. Regulatory posture — on-pathway only
We operate strictly within the named-patient, personal-importation, and compassionate-use pathways recognized in each destination country. We do not operate in regulatory gray zones, do not ship to jurisdictions where the pathway does not exist or has been suspended, and do not assist in circumventing a country's pharmaceutical regulatory authority.
4. No controlled substances, no reverse flow
We do not handle DEA-scheduled controlled substances. Our direction of trade is strictly US → overseas patient; we do not operate reverse-flow (overseas-to-US) routes.
5. Commercial independence
Reserve Meds receives no payments, rebates, or in-kind support from manufacturers tied to volume or therapy selection. Our clinical content is not sponsored. When we publish pricing, it reflects our actual sourcing economics, not a manufacturer's listing.
6. Conflict disclosure
Leadership and clinical advisors disclose all material relationships annually. Where a relationship could influence a sourcing or content decision, the individual recuses from that decision and the recusal is logged in our governance register.
7. Escalation
Any employee, physician, partner, or patient who believes a decision has violated this policy may raise it directly to the CEO at [email protected] or, if unresolved, to outside counsel via our whistleblower channel. Retaliation for good-faith reporting is grounds for termination.
Reviewed 2026-04-22 by Reserve Meds's AI Pharmacist and AI Regulatory Counsel. Next scheduled review: 2026-10-22.